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The aim of this study was to collect data from patients who underwent liver transplantation (LT) for adenomatosis; to
analyze the symptoms, the characteristics of the disease, and the recipient outcomes; and to better define the role of LT in
this rare indication. This retrospective multicenter study, based on data from the European Liver Transplant Registry,
encompassed patients who underwent LT for adenomatosis between January 1, 1986, and July 15, 2013, in Europe.
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had GSD, and 7 had liver vascular abnormalities. The main indications for transplantation were either a suspicion of
hepatocellular carcinoma (HCC; 15 patients) or a histologically proven HCC (16 patients), but only 17 had actual malig-
nant transformation (MT) of adenomas. GSD status was similar for the 2 groups, except for age and the presence of
HCC on explants (P 5 0.030). Three patients with HCC on explant developed recurrence after transplantation. We
obtained and studied the pathomolecular characteristics for 23 patients. In conclusion, LT should remain an extremely
rare treatment for adenomatosis. Indications for transplantation primarily concern the MT of adenomas. The decision
should rely on morphological data and histological evidence of MT. Additional indications should be discussed on a case-
by-case basis. In this report, we propose a simplified approach to this decision-making process.
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Multiple adenomas (MAs) occur either in normal livers
or in cases of underlying liver pathology, such as glycogen
storage disease (GSD) or congenital or acquired vascular
anomalies. Initially, Flejou et al.(1) described a special
entity, liver adenomatosis (LA), in cases with more than
10 adenomas in a normal liver in the absence of GSD or
vascular disease. Great progress has been made in the
diagnosis, imaging, and pathogenicity of adenomas. In
particular, the quality of nontumoral parenchyma is
important in the management of MAs. So, considering
the recent advances in this field, the term of adenomatosis
has been extended and refers today to a high number of
these tumors in the liver.(2) LA is a heterogeneous disease,
and imaging often underestimates the number of lesions
present. Chiche et al.(3) described 2 forms of LA: a mas-
sive form with an enlarged liver and typically large and
necrotic tumors, and a multifocal form with a normal-
sized liver in which 1 or 2 adenomas may predominate
over the smallest lesions.
The risks of hemorrhage and malignant transforma-
tion (MT) justify tumor resection in many cases of sol-
itary hepatocellular adenoma (HCA).(4-10) However,
this surgical approach can be difficult or impossible in
cases of LA due to the large number of adenomas.
Therefore, liver transplantations (LTs) have been
reported in the literature.(11-17) Nevertheless, the man-
agement of LA remains controversial despite some
progress in the prediction of the potential risk of com-
plications (which is likely related to the size and bio-
molecular subtypes of the adenomas), and LA
management ranges from simple follow-up to partial
or total liver resection.(18-21)
This report describes a large retrospective European
cohort of LT patients treated for adenomatosis and
examines the main factors leading to transplantation
and the transplantation results, with the goal of identi-
fying the optimal role for LT in LA. This study also
provides recommendations for LT decision-making
in LA.
Patients and Methods
Prospectively collected data from the European Liver
Transplant Registry (ELTR)(22) were reviewed after
obtaining approval from the board of the European
Liver and Intestine Transplant Association. Patients
undergoing LT for LA between January 1, 1986, and
July 15, 2013, were selected. Patients with GSD type
IA who underwent LT for LA were included.
The ELTR has collected prospective data on LT in
145 centers all over Europe since 1968. We selected
cases with the diagnostic code “adenomatosis” in the
ELTR database. A standard computerized file was
provided to the contributing centers with detailed
instructions for the collection of accurate and uniform
information. However, participation in the ELTR is
voluntary and may contain coding errors. Therefore,
we directly contacted the centers and, notably, all of
the French and Belgium centers to check the validity
of the ELTR list. Patients were included only if the
primary indication was LA (exclusion of hepatocellular
insufficiency).
DATA COLLECTION
Each transplant center received the project summary
and was contacted to obtain detailed medical files after
patient identification. All of the centers were asked to
send the medical files (main preoperative consultation;
radiological, surgical, histopathological reports; and
date of last news or death). The files were processed at
the coordinating center at Bordeaux, France. Process-
ing included record review to confirm the diagnosis
and exclude possible errors.
Histological and primarily pathomolecular data were
very laborious to obtain. Twelve centers sent us patho-
logic tissue blocs for secondary examination by our path-
ological expert in Bordeaux (Paulette Bioulac-Sage).
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DISEASE
The clinical manifestations that led to the adenomato-
sis diagnosis were reported as follows: “abdominal pain
and hepatomegaly”; “hemorrhage,” which included
patients who had severe bleeding episodes; or “others,”
which included rare signs, such as pruritus. When
diagnosis of LA was done fortuitously by imaging or in
the follow-up of different pathologies, the patient was
classified in “no symptoms.”
We identified 2 forms of adenomatosis as defined
by Chiche et al.,(3) ie, massive or multifocal forms.
After careful review of all the clinical reports, indica-
tions for LT were reclassified into 5 main groups:
“hepatocellular carcinoma (HCC) confirmed,” which
included patients who had the diagnosis of MT by a
biopsy or on a surgical specimen; “suspicion of HCC”
as noted in the files as indications for LT; “evolution,”
which included patients who had LA with progression
in size or number of adenomas; “hemorrhage,” for
patients who had iterative or life-threatening hemor-
rhagic manifestations; and “symptoms” if patients pre-
sented with severe pain or disability associated with
liver enlargement.
The populations with and without GSD were stud-
ied separately to identify whether this underlying dis-
ease should be considered a separate entity, and the
risk factors of MT were investigated.
STATISTICAL ANALYSIS
Patient and follow-up data were obtained from the elec-
tronic medical record we created. Proportions were
compared using the chi-square test or Fisher’s exact test
as indicated. P values < 0.05 were considered significant
in all analyses. Statistical analyses were performed using
the R program, version 2.15.1 (R Foundation for Statis-
tical Computing, Vienna, Austria) and the statistical
software STATA (Statacorp, College Station, TX).
There were missing data regarding, for instance,
oral contraception or the number of HCAs. We
included missing data in the statistical analyses when
these data represented more than 10% of the value.
Results
According to the ELTR, 64 patients were identified as
having a LT for LA in 22 centers in 5 European coun-
tries during the study period. Several centers did not
provide data, others reported more or less cases than
the registered number in the ELTR database, and sev-
eral coding errors were identified.
Additional cases were collected after direct calls to
the French centers. Thirteen French centers reported
24 patients, but only 5 of these patients were listed in
the ELTR database. Two Belgium centers reported 6
patients; 4 Italian centers reported 7 patients; 2 Span-
ish centers reported 3 patients; and 1 German center
reported 9 patients.
Eventually, a total of 49 patients underwent a LT for
histologically confirmed adenomatosis throughout this
long period, quite consistently, because 30 underwent
transplantation before 2006 and 19 underwent trans-
plantation after (Fig. 1). Table 1 shows the patient char-
acteristics. Thirty-one of the 49 (63%) patients were
women, and 18 (37%) patients were men. Information
on estrogen intake was not available in 12/31 women,
even after advanced research. In the other 19 female
patients, only 6 had a history by oral contraceptive
intake. The following initial clinical manifestations of
the disease were noted: 22 follow-up cases (14 for glyco-
genosis); 6 cases of abdominal pain with hemorrhagic
manifestations; 6 cases of accidental discovery, including
trauma in most cases; and 4 cases of hepatomegaly.
Twenty-seven of the 49 (55%) patients were younger
than 30 years. We obtained information for maturity
onset diabetes of the young (MODY) 3 diabetes(23-25)
for 2 patients, and 2 patients had a family history of
adenomatosis, including 2 sisters in this study. Sixteen
(33%) patients had GSD type IA in this study.
DISEASE
Twenty-eight (57%) patients had the massive form of
adenomatosis, and 21 (43%) patients had the multifocal
form. Table 1 shows the characteristics of the cases.
Thirty (61%) patients had more than 10 HCA on the
final hepatectomy, and 4 (8%) patients had exactly 10 or
fewer. Fourty (82) patients had LA>4 cm, as compared
to 9 (18%) patients who exhibited LA 4 cm (patients
with GSD or with a history of previous hepatectomies
for larger adenomas).
We identified 7 (14%) patients with underlying vas-
cular disease, which is a well-known factor(26-29) in the
pathogenesis of benign liver tumors and pseudotumors.
The histology was confirmed in those cases by 2 path-
ologists. One patient had a history of Tetralogy of Fal-
lot that was treated with surgery and a splenorenal
shunt. Four patients had portocaval shunts in child-
hood (including one for agenesis of portal vein) one
had a portocaval congenital shunt and one Osler
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Weber Rendu disease. One patient had GSD with vas-
cular abnormalities.
INDICATION FOR LT AND
TRANSPLANTATION
MANAGEMENT
Table 1 shows the following indications for LT: 15
(31%) patients received LT for suspicion of MT; 16
(33%) patients underwent transplantation for HCC
that was histologically proven before LT (by biopsy [n
5 4] or on a surgical specimen of a previous hepatec-
tomy [n 5 12]). Patients who had biopsy underwent
transplantation for HCC; and in patients who had
HCC on a surgical specimen, LT was decided either
as a preventive procedure, considering the risk of
malignancy in the remaining adenomas or as a curative
after recurrence. Eight (16%) patients underwent LT
due to disease progression (size and number of adeno-
mas); 5 (10%) patients underwent LT for hemorrhagic
manifestations—1 life-threatening cataclysmic hemor-
rhagic justified the indication of LT in an emergency,
and 4 patients received emergency surgery with liver
resection for intraperitoneal bleeding; and 5 (10%)
patients received LT for symptomatic adenomas with-
out the possibility of simple hepatic resection. Twenty-
one of the 49 (43%) patients had a history of 1 or sev-
eral hepatic resections, and 2 (4%) patients had
received embolization for hemorrhage before LT. Five
(10%) patients received more than 1 LT; 2 (4%)
patients underwent simultaneous kidney transplanta-
tion (patients with GSD); and 3 (6%) patients received
a LT from a living donor.
PATHOLOGICAL
CHARACTERISTICS
We obtained 23 pathomolecular characteristics. The
results (hepatocyte nuclear factor [HNF] 1a, inflamma-
tory (IHCA), b-catenin [b-CAT], or mixed subtypes)
are reported in Table 2. In patients without GSD,
HNF1a mutation was observed in 10/16 patients; in
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FIG. 1. Selection of patients for this study from the ELTR and French and Belgium centers.
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patients with GSD and available data, the inflammatory
subtype was predominant with or without b-CAT
mutation. This study identified 17 (35%) patients with
MT (Table 3). Sixteen (33%) patients had HCC that
was confirmed before LT and diagnosed by biopsy or
hepatic surgery. Only 1 patient was transplanted for the
suspicion of HCC and showed MT on the liver explant.
Table 3 shows the clinical and molecular characteristics
of patients with HCC: 8 of the 17 patients had multifo-
cal MT and each pathomolecular type has been
observed. Only 1 of the patients transplanted for suspi-
cion of MT (including the 10 GSD patients) showed
actual HCC.
GSD STATUS
Table 4 compares the patients with GSD type IA and
without. Patients in the GSD group were significantly
younger (P 5 0.034) and had larger livers than the
group without GSD (P 5 0.002) at the time of LT.
The patients without GSD more often (10/17) had
the diagnosis of HCC confirmed before LT (P 5
0.030). There was no significant difference in the
global risk of HCC (confirmed before or after LT)
between GSD and non-GSD patients.
LONGTERM OUTCOMES
No patient was lost during follow-up. The median
duration of survival was 108 months (24-168 months),
with a range of 0-316 months. Three patients died
within 90 days after LT because of severe pulmonary
edema, sepsis (biliary duct necrosis), and hemorrhagic
shock after his second transplantation. These 2 last
operative deaths occurred before 2000 and concerned
patients with vascular abnormalities or previous liver
surgery. Two patients died after 3 years of follow-up;
of these, 1 patient died of lymphoma, and the other
patient died in unknown circumstances. Three of the
17 patients with HCC in liver explants experienced
recurrence after LT and died of the disease. So, in
2014, 41/49 patients were alive and well.
The median duration of GSD was 74 months (13-
141 months), with a range of 0 to 316 months. The
indications for retransplantation: hemorrhagic shock in
1 patient and severe biliary complications (ischemic
cholangiopathy in 2 patients and chronic rejection in 2
patients).
Analyses of the factors associated with MT revealed
that only age > 30 years and history of partial hepatec-
tomies were statistically significant (Table 5). The
characteristics of the LA and the underlying disease
were not significantly associated with MT.
Discussion
LA is a benign disease, although 2 potential lethal risks
may justify aggressive management: cases of the mas-
sive form with complications, such as iterative and/or
severe bleeding, and cases showing MT.
This ELTR study is the largest cohort of LT in LA
reported in the literature. Although we only identified
21 patients who received LT for adenomatosis without
GSD in the English language literature, our series of
TABLE 1. Patient and LT Characteristics
Value (n 5 49)
Patients characteristics
Sex
Female 31 (63)
Male 18 (37)
Age
30 years 27 (55)
>30 years 22 (45)
GSD 16 (33)
MODY 3 2 (4)
Clinical manifestation
No 33 (67)
Pain and hepatomegaly 10 (20)
Hemorrhage 6 (12)
Liver and adenomatosis characteristics
Underlying liver pathology
GSD 15 (31)
Vascular abnormalities 6 (12)
GSD and vascular abnormalities 1 (2)
Form
Massive 28 (57)
Multifocal 21 (43)
Number of HCAs
Missing data 15 (31)
10 4 (8)
>10 30 (61)
Biggest size (cm)
4 9 (18)
>4 40 (82)
Bleeding history 11 (22)
Transplant history
Liver surgery before LT 21 (43)
Embolization before LT 2 (4)
Transplantation type
 2 LT 5 (10)
Kidney and LT 2 (4)
Living donor 3 (6)
Indication of LT
HCC confirmed 16 (33)
HCC suspected 15 (31)
Disease progression 8 (16)
Hemorrhage 5 (10)
Symptoms 5 (10)
NOTE: Data are given as n (%).
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33 patients without GSD is the largest reported to
date (Table 6).
This study first described a population of trans-
planted patients to analyze the primary factors that
lead to transplantation in current practice. Several
interesting findings from the data emerged from our
analyses. First, we observed a predominance of
women (63%) but a lower incidence compared to the
usual HCA population. The median age was 28 years
(23-41), and more than half of the patients were
younger than 30 years old. Notably, we expected to
find a large number of massive and highly sympto-
matic forms, but we found that 75% of the trans-
planted patients were asymptomatic. Specifically,
43% of the patients presented multifocal disease, and
the maximal size of the adenomas in 9 (18%) patients
TABLE 2. Biomolecular Characterization of HCA Developed in Patients Who Had LT for MAs
Number Liver HCC Form Biomolecular Group Number of HCA Size
1 GSD Multiple IHCA 20 6
2 GSD 1 Massive b-CAT 1 b-IHCA >10 15
3 GSD 1 Multiple IHCA 22 4
4 GSD Multiple b-CAT1 b-IHCA 1 IHCA >10 2
5 GSD Multiple b-CAT1 b-IHCA 1 IHCA >10 3
6 GSD Multiple IHCA >10 5
7 GSD 1 Massive IHCA >10 11
8 VASC 1 Massive HNF1a >10 4
9 VASC 1 Multiple HNF1a NR 8
10 VASC 1 Massive b-CAT 50 13
11 VASC Massive HNF1a 2 17
12 VASC Multiple Unclassified >10 4
13 Massive HNF1a >10 10
14 Massive HNF1a >10 8
15 Multiple IHCA 8 8
16 Multiple HNF1a >10 5
17 1 Massive IHCA 39 8
18 1 Massive b-CAT 1 b-IHCA 50 9
19 Massive HNF1a >10 8
20 Massive HNF1a >10 10
21 Multiple HNF1a >10 6
22 Massive HNF1a 22 18
23 Massive IHCA >10 8
TABLE 3. Clinical and Pathologic Characteristics of MTs Developed in Patients Who Had LT
Number Age, years Sex Liver Form
HCC Before
TH Explant HCC
Number of
HCC on Liver
Explant
Number of
HCC Total
Biomolecular
Group
1 64 Female Multiple Yes Yes Multifocal Multiple
2 34 Female Massive Yes Yes Multifocal Multiple IHCA
3 43 Male Multiple Yes Yes Multifocal Multiple
4 47 Female Massive Yes Yes Multifocal Multiple b-CAT/CAT/
IHCA and IHCA
5 38 Female Multiple Yes ND Single
6 41 Female Multiple Yes Yes Unifocal Single
7 51 Female Multiple Yes Yes Unifocal Multiple
8 47 Female Massive Yes Yes Unifocal Single
9 43 Female Multiple Yes No No Single
10 31 Male VASC Massive Yes Yes Multifocal Multiple b-CAT
11 26 Male VASC Massive Yes Yes Multifocal Multiple HNF1a
12 27 Male VASC Multiple Yes Yes Unifocal Single HNF1a
13 39 Female GSD1VASC Massive Yes Yes Multifocal Multiple b-CAT/IHCA
and IHCA
14 32 Male GSD Multiple Yes No No Single IHCA
15 21 Female GSD Massive No Yes Unifocal Single IHCA
16 25 Female GSD Massive Yes (B) No No Single
17 23 Female GSD Multiple Yes (B)
(Borderline)
No No Single
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was 4 cm in liver explants, but this concerned
patients who had undergone previous hepatectomies
or patients with liver disease hampering the possibil-
ity of partial hepatectomies.
Concerning the indication of LT, because hemor-
rhage appeared to be the main indication in this disease
in the case reports of the literature we expected to collect
a higher percentage of patients transplanted for hemor-
rhage in this study. However, only 5 patients underwent
transplantation for this complication: 1 patient had dra-
matic hemorrhage with a history of several previous par-
tial resections, and 4 patients presented with underlying
liver disease that contraindicated resection. Iterative
severe or life-threatening hemorrhages are rare in LA.
Moreover, we have an expanding armamentarium and
experience in controlling bleeding angiographically, so
this indication of LT should remain exceptional. It
should be restricted to hemorrhages in case of failure or
impossibility of embolization and/or partial hepatec-
tomy, because of the location of the bleeding tumor, the
number of hemorrhages, or the underlying liver disease.
The concern of malignancy happens to be, in this
series, the major indication. Two situations were
observed before transplantation: (1) a proven diagnosis
of MT of 1 adenoma or (2) the fear of malignancy. In
the first case, the transformation of 1 or more HCAs
among lots of other nodules was a major concern,
which explains the decision to perform LT. In 1
patient, this decision was likely too late because the
disease was obviously progressive and HCC in the liver
explant was very advanced.
The second situation, the fear of malignancy, is
more debatable. Notably, we observed that 14 (75%)
patients with GSD underwent transplantation for
HCC suspicion or disease progression, although only 4
(25%) patients with GSD had HCC that was histolog-
ically confirmed before LT. Twelve (36%) patients
without GSD underwent transplantation with histo-
logical proof of HCC, and 11 (33%) patients under-
went transplantation for HCC suspicion or disease
progression without histological proof. The risk of
malignancy was clearly overestimated in the group
with GSD because the literature considers this under-
lying disease as a risk factor for the MT of adeno-
mas.(8) These data are supported by a high frequency
of b-CAT–mutated adenomas(5,7) in this pathology.
TABLE 4. Clinical and Pathological Characteristics
According to the GSD Status
No GSD
(n 5 33)
GSD
(n 5 16) P Value
Sex 0.35
Female 23 (70) 8 (50)
Male 10 (30) 8 (50)
Age 0.034
30 years 14 (42) 13 (81)
>30 years 19 (58) 3 (19)
Patient weight (kg) 0.015
60 11 (33) 11 (69)
>60 22 (67) 5 (31)
LA form 0.45
Massive 19 (58) 8 (50)
Multifocal 14 (42) 8 (50)
Number of HAs 0.49
Missing data 8 (24) 7 (44)
10 3 (9) 1 (6)
>10 22 (67) 8 (50)
Biggest size (cm) 0.07
4 3 (9) 6 (38)
>4 30 (91) 10 (63)
Liver weight (kg) 0.002
Missing data 5 (15) 1 (6)
2.5 19 (58) 3 (19)
>2.5 9 (27) 12 (75)
Vascular liver abnormalities 6 (18) 1 (6) 0.96
Hemorrhagic intratumoral 10 (30) 1 (6) 0.11
Indication of LT
HCC confirmed 12 (36) 4 (25)
Suspicion of HCC 5 (15) 10 (63)
Disease progression 6 (18) 2 (13)
Hemorrhagic 5 (15) 0 (0)
Symptomatic without
possibility of liver resection
5 (15) 0 (0)
HCC confirmed on the liver explant 10 (59) 2 (13) 0.030
HCC confirmed before or after LT 12 (36) 5 (31) 0.62
NOTE: Data are given as n (%).
TABLE 5. Patient and Adenomatosis Characteristics for
Patients With HCC
No HCC
(n 5 32)
HCC
(n 5 17) P Value
Sex 0.54
Female 19 (59) 12 (71)
Male 13 (41) 5 (29)
Age 0.016
30 years 22 (69) 5 (29)
>30 years 10 (31) 12 (71)
GSD
Yes 11 (34) 5 (29) 0.75
No 21 (66) 12 (71)
Vascular abnormalities 0.23
Yes 3 (9) 4 (24)
No 29 (91) 13 (76)
LA form 0.38
Massive 20 (62) 8 (47)
Multifocal 12 (38) 9 (53)
Surgical history 0.013
Yes 10 (31) 11 (65)
No 22 (69) 6 (35)
Hemorrhagic form 0.46
Yes 9 (28) 2 (12)
No 23 (72) 15 (88)
NOTE: Data are given as n (%).
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We identified nearly 37 patients transplanted for MAs
and GSD in the literature, but only 6 patients showed
evidence of HCC in liver explants. Therefore, 85% of
the patients who underwent transplantation for ade-
noma exhibited no HCC on liver explants, both in our
study and in the literature. However, patients with
GSD underwent transplantation earlier than other
patients (median age was statistically lower), perhaps
before MT.
MT was a frequent feature in patients with vascular
disease associated with adenomas, as this presentation
occurred in 4 of the 7 patients. However, it was not
statistically relevant in our analyses of risk factors,
likely because of the low number of these cases.
In the 9 patients with normal livers, (1) the median
age was higher; (2) the form of LA, either massive or
multifocal, was usually evolutive; and (3) the MT was
multifocal in liver explants in 5 of the 9 patients.
These data demonstrate that follow-up must be rec-
ommended in LA to diagnose this lethal complication.
However, implementation of this follow-up approach
is not clearly established. Magnetic resonance imaging
may be the best method to study increases in adenoma
size or intratumoral modifications with apparitions of a
portal washout, and biopsy or surgical exploration
should also be discussed. The means and timing of
follow-up in LA should likely be adaptable in this het-
erogeneous disease. Follow-up must be frequent and
accurate in evolutive forms of adenomas and in patients
with vascular disease or a b-CAT mutation, whereas
follow-up can be less frequent in nonevolutive forms of
the disease and in patients with small adenomas, par-
ticularly young patients, using ultrasonography for
basic routine examinations. In addition, patient age
>30 years was statistically associated with malignancy.
Analyses of biomolecular pathways revealed another
interesting finding of this study. Biomolecular studies
are not performed in all centers, which is why we did
not obtain complete data for our 49 patients. Never-
theless, even when incomplete, these data are informa-
tive. The HNF1a subgroup was the most frequent
feature in LA without liver disease or GSD, as
reported in the literature; however, we also observed
that different biomolecular subgroups of adenomas
could be present in the same patient(41) and that MT
was possible across biomolecular subtypes, even in the
HNF1a group (2 HCCs with underlying vascular dis-
ease of the liver). Therefore, more data are mandatory
to better understand the link between HCC and bio-
molecular subtype, and it is clear that the risk of malig-
nancy, in the case of adenomatosis, should not be
stated only on the biopsy of 1 sole adenoma and does
not exclusively concern b-CAT–mutated adenomas.
The clinical results of LT in this series were rela-
tively good (41 patients alive and well), although 43%
of the patients had undergone previous liver surgery
and some had vascular abnormalities. Nevertheless, we
must take into account the 3 operative deaths and 5
retransplantations, which is not negligible. Transplan-
tation teams have to assess the potential technical diffi-
culties of LT related to prior vascular or hepatic
surgery. This past history may be a factor of operative
bleeding and/or morbimortality. So, the performance
of preventive LT is debatable, although the opposite
risk is delayed transplantation after the MT of several
tumors. The patients with MT who recurred after LT
died of the disease. These 3 patients had massive LA
with multifocal HCC identified on liver explants. One
of these 3 patients had vascular abnormalities; 1 patient
had GSD and vascular abnormalities; and 1 patient
had no underlying liver disease (no GSD, no vascular
abnormalities). However, all 3 patients had advanced
HCC in liver explants with vascular involvement
(obvious for 2 patients on preoperative imaging),
which is a well-known very poor prognostic factor.
Like in transplantation for HCC, diagnosis of vascular
invasion on imaging should indeed be an absolute con-
traindication to transplantation. In conclusion, MT
seems to be a good indication if it is not too advanced.
This implies that in the case of suspicion of MT,
TABLE 6. Literature Review: LT for Adenomatosis Without
and With GSD
Reference n
HCC explant
transformation
Patients without GSD
Leese et al.(30) (1988) 1 HCC
Marino et al.(31) (1992) 4 No
Yoshidome et al.(32) (1999) 6 ND
Chiche et al.(3) (2000) 2 HCC
Yunta et al.(33) (2001) 1 HCC
Fujita et al.(27) (2006) 1 No
Wellen et al.(17) (2010) 1 No
Dokmak et al.(18) (2009) 1 ND
Di Sandro et al.(34) (2009) 1 HCC
Vennarecci et al.(21) (2013) 1 HCC
Gordon-Burroughs et al.(35) (2014) 1 HCC
Fernandez-Vega et al.(36) (2014) 1 No
Patients with GSD IA
Matern et al.(14) (1999) 14 No
Labrune(15) (2002) 1 HCC
Lerut et al.(13) (2003) 1 HCC
Franco et al.(37) (2005) 1 HCC
Arikan et al.(38) (2006) 13 No
Davis and Weinstein(39) (2008) 4 No
Reddy et al.(16) (2009) 1 HCC
Manzia et al.(40) (2011) 2 HCC
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diagnosis has to be rapidly confirmed in order to dis-
cuss LT without delay.
Even with this study, it is difficult or impossible to
provide evidence-based recommendations for the indi-
cation of LT in LA. It should be discussed with cau-
tion because of the benign nature of this disease, the
mortality of LT, and liver graft shortage. Some authors
have stated that there is no indication for transplanta-
tion in LA,(18) and this series demonstrates the oppo-
site. Nevertheless, 1 major problem is the access to LT
for these patients without cirrhosis and therefore with
low Model for End-Stage Liver Disease (MELD)
score. Several years ago (approximately before 2006-
2007 in Europe), before MELD score was adopted for
organ allocation, patients with LA had access to trans-
plant quite easily. Today, with the European alloca-
tion’s rules based on MELD score, those patients can
be transplanted only as MELD exceptions or with liv-
ing donors (3 in this series). That is why it is important
to define the good candidates for transplantation. In
most patients, it seems that the indication for LT will
not depend on a single factor.
We identified a list of data correlated with a life-
threatening form of LA. The proof of MT is serious
enough by itself to justify LT: this represents the so-
called major criterion. Other clinical or pathological
factors (minor criteria) have been noted as risk factors
of malignancy or hemorrhage in the literature and in
our series (such as b-CAT–mutated adenomas or
(IHCA) age >30 years) or reasons for not performing
partial resections (liver vascular anomalies or a history
of iterative hepatectomies). These factors may consti-
tute cumulative arguments for aggressive treatment,
but they should not be a justification for transplanta-
tion in isolation. Using those different criteria, in order
to aid the decision-making process, we recommend a
discussion of LT when the patient has either the major
criterion or at least 3 minor criteria (Table 7):
1. Major criteria: HCC (biopsy or surgical specimen).
2. Minor criteria:
a. More than 2 serious (life-threatening)
hemorrhages.
b. More than 2 previous hepatectomies.
c. Beta-mutated or inflammatory adenomas.
d. Underlying liver disease (major steatosis or vas-
cular abnormalities).
e. Age > 30 years.
Our results highlight the crucial necessity of precise
histological study of several adenomas (pathomolecular
characteristics and mandatory proof of MT) and non-
tumoral livers before any discussion of LT. This study
also supports that the restrictive definition of LA that
excludes GSD or vascular disease is not justified even
if these underlying pathologies influence the manage-
ment of these patients.
In conclusion, this study demonstrates that LA is
an extremely rare indication for LT, representing
approximately 0.03% of LTs in Europe, which should
be validated in cases of exceptionally aggressive types
of this disease. Considering the characteristics of this
population (previous liver surgery, liver underlying dis-
ease, vascular abnormalities), LT is associated with a
significant rate of morbimortality. On the other hand,
many complications of this benign disease can be
handled by modern radiological or surgical approaches.
If not, mostly in case of MT, and after assessment of
the risk-benefit ratio, this European experience shows
that LT can be justified. However, the access to LT
depends on an expert decision because the system of
graft allocation is based on the MELD score, and LA
has no impact on liver function. Therefore, the identi-
fication of several criteria is mandatory to aid the
decision-making process.
The strength of this multicenter series was the col-
lection of information on extremely rare diseases.
These results should serve as a catalyst to initiate pro-
spective multicenter studies to address the many
remaining issues of this rare disease, such as the identi-
fication of high-risk patients, prediction of malignancy,
and the timing of LT. A prospective worldwide regis-
try of patients transplanted for LA, with extensive
study of history, pretransplant modern imaging, and
precise pathological examination of the explanted liver
with biomolecular characterization would be the best
way to progress in that heterogeneous and complex
rare disease.
TABLE 7. Criteria Leading to LT in Adenomatosis in
Our Center
Criterion
Number of
Criteria
Required
Major criteria Histological proof of MT in 1
(or more) adenoma
1
Minor criteria More than 2 life-threatening
hemorrhages
More than 2 previous
hepatectomies
Beta-mutated or inflammatory
adenomas
Underlying liver disease
Age > 30 years
3 or more
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